Abstract
EBV-induced post transplant lymphoproliferative disorder (PTLD) continues to be a major complication after transplantation. Between January 1993 and April 2006, 12 cases of B-cell lymphoproliferative disorder were identified among 577 patients after allogeneic hematopoietic SCT (HSCT) with an overall incidence of 2.51% at 1 year. Grades II–IV acute GVHD, CMV antigenemia and the use of antithymocyte globulin (ATG) were independent risk factors for PTLD. At diagnosis, all of the tumors were CD20-positive and 11 (92%) were EBV-encoded RNA (EBER)-positive. Of the 12 patients with B-cell lymphoproliferative disorder, 8 had pulmonary involvement and 10 had extranodal involvement. Eleven patients received weekly rituximab therapy at a dose of 375 mg/m2; the median interval between the onset of symptoms and rituximab therapy was 6 days. The overall mortality rate was 92% and seven (64%) of the deaths were directly attributable to disseminated PTLD within days or weeks of presentation. In our series, pulmonary PTLD followed an extremely aggressive course and poor response to current therapy, even though rituximab was included in the therapeutic regimens.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Nalesnik MA, Jaffe R, Starzl TE, Demetris AJ, Porter K, Burnham JA et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A–prednisone immunosuppression. Am J Pathol 1988; 133: 173–192.
Cohen JI . Epstein–Barr virus lymphoproliferative disease associated with acquired immunodeficiency. Medicine (Baltimore) 1991; 70: 137–160.
Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL . Epstein–Barr virus, immunodeficiency, and B cell lymphoproliferation. Transplantation 1985; 39: 461–472.
Blazar B, Patarroyo M, Klein E, Klein G . Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein–Barr viral cycle by superinfection or sodium butyrate. J Exp Med 1980; 151: 614–627.
Pearson GR, Orr TW . Antibody-dependent lymphocyte cytotoxicity against cells expressing Epstein–Barr virus antigens. J Natl Cancer Inst 1976; 56: 485–488.
Wallace LE, Rickinson AB, Rowe M, Epstein MA . Epstein–Barr virus-specific cytotoxic T-cell clones restricted through a single HLA antigen. Nature 1982; 297: 413–415.
Gross TG, Steinbuch M, DeFor T, Shapiro RS, McGlave P, Ramsay NK et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant 1999; 23: 251–258.
Shapiro RS, McClain K, Frizzera G, Gajl-Peczalska KJ, Kersey JH, Blazar BR et al. Epstein–Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234–1243.
Witherspoon RP, Fisher LD, Schoch G, Martin P, Sullivan KM, Sanders J et al. Secondary cancers after bone marrow transplantation for leukemia or aplastic anemia. N Engl J Med 1989; 321: 784–789.
Zutter MM, Martin PJ, Sale GE, Shulman HM, Fisher L, Thomas ED et al. Epstein–Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520–529.
Curtis RE, Travis LB, Rowlings PA, Socie G, Kingma DW, Banks PM et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999; 94: 2208–2216.
Knowles DM, Cesarman E, Chadburn A, Frizzera G, Chen J, Rose EA et al. Correlative morphologic and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995; 85: 552–565.
d'Amore ES, Manivel JC, Gajl-Peczalska KJ, Litz CE, Copenhaver CM, Shapiro RS et al. B-cell lymphoproliferative disorders after bone marrow transplant. An analysis of ten cases with emphasis on Epstein–Barr virus detection by in situ hybridization. Cancer 1991; 68: 1285–1295.
Bhatia S, Ramsay NK, Steinbuch M, Dusenbery KE, Shapiro RS, Weisdorf DJ et al. Malignant neoplasms following bone marrow transplantation. Blood 1996; 87: 3633–3639.
Kernan NA, Bartsch G, Ash RC, Beatty PG, Champlin R, Filipovich A et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Engl J Med 1993; 328: 593–602.
Cohen J, Gandhi M, Naik P, Cubitt D, Rao K, Thaker U et al. Increased incidence of EBV-related disease following paediatric stem cell transplantation with reduced-intensity conditioning. Br J Haematol 2005; 129: 229–239.
Deeg HJ, Socie G . Malignancies after hematopoietic stem cell transplantation: many questions, some answers. Blood 1998; 91: 1833–1844.
Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G et al. Epstein–Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517–1525.
Starzl TE, Nalesnik MA, Porter KA, Ho M, Iwatsuki S, Griffith BP et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984; 1: 583–587.
Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehee A et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115: 112–118.
Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11 (Suppl 1): 113–116.
Straathof KC, Savoldo B, Heslop HE, Rooney CM . Immunotherapy for post-transplant lymphoproliferative disease. Br J Haematol 2002; 118: 728–740.
Elstrom RL, Andreadis C, Aqui NA, Ahya VN, Bloom RD, Brozena SC et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006; 6: 569–576.
Choquet S, Leblond V, Herbrecht R, Socie G, Stoppa AM, Vandenberghe P et al. Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study. Blood 2006; 107: 3053–3057.
Oertel SH, Verschuuren E, Reinke P, Zeidler K, Papp-Vary M, Babel N et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005; 5: 2901–2906.
Benkerrou M, Jais JP, Leblond V, Durandy A, Sutton L, Bordigoni P et al. Anti-B-cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998; 92: 3137–3147.
Hoshino Y, Kimura H, Kuzushima K, Tsurumi T, Nemoto K, Kikuta A et al. Early intervention in post-transplant lymphoproliferative disorders based on Epstein–Barr viral load. Bone Marrow Transplant 2000; 26: 199–201.
Cesaro S, Murrone A, Mengoli C, Pillon M, Biasolo MA, Calore E et al. The real-time polymerase chain reaction-guided modulation of immunosuppression enables the pre-emptive management of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation. Br J Haematol 2005; 128: 224–233.
Rooney CM, Loftin SK, Holladay MS, Brenner MK, Krance RA, Heslop HE . Early identification of Epstein–Barr virus-associated post-transplantation lymphoproliferative disease. Br J Haematol 1995; 89: 98–103.
Stevens SJ, Verschuuren EA, Pronk I, van Der Bij W, Harmsen MC, The TH et al. Frequent monitoring of Epstein–Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood 2001; 97: 1165–1171.
Wagner HJ, Cheng YC, Huls MH, Gee AP, Kuehnle I, Krance RA et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979–3981.
Gustafsson A, Levitsky V, Zou JZ, Frisan T, Dalianis T, Ljungman P et al. Epstein–Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells. Blood 2000; 95: 807–814.
van Esser JW, van der Holt B, Meijer E, Niesters HG, Trenschel R, Thijsen SF et al. Epstein–Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood 2001; 98: 972–978.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hou, HA., Yao, M., Tang, JL. et al. Poor outcome in post transplant lymphoproliferative disorder with pulmonary involvement after allogeneic hematopoietic SCT: 13 years' experience in a single institute. Bone Marrow Transplant 43, 315–321 (2009). https://doi.org/10.1038/bmt.2008.325
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2008.325
Keywords
This article is cited by
-
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
Bone Marrow Transplantation (2024)
-
Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation (2024)
-
Epstein–Barr virus-positive lymphoproliferative disorder manifesting as pulmonary disease in a patient with acute myeloid leukemia: a case report
Journal of Medical Case Reports (2021)
-
Post-transplantation lymphoproliferative disorder after haematopoietic stem cell transplantation
Annals of Hematology (2021)
-
Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities
Bone Marrow Transplantation (2020)